BERKELEY, Calif., June 11 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation announced today Deborah Smeltzer, Chief Financial Officer, will present an overview of the company at the Sixth Annual Needham Biotechnology and Medical Technology Conference in New York, New York on Thursday, June 14 at 9:30 a.m. Eastern Daylight Savings Time (6:30 a.m. PDST). The presentation will be webcast.
To access the live audio broadcast and the subsequent archived audio recording of the company presentation, please log onto the company’s website at http://www.dynavax.com under the “Investors’” section.
ABOUT DYNAVAX
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV, a hepatitis B vaccine in Phase 3; TOLAMBA, a ragweed allergy immunotherapy; a therapy for non-Hodgkin’s lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. Our preclinical work on a vaccine for influenza is partially funded by the NIH. Our colorectal cancer trial and our preclinical hepatitis C therapeutic program are funded by Symphony Dynamo, Inc. While the NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.
Dynavax Technologies Corporation
CONTACT: Shari Annes of Dynavax Technologies Corporation InvestorRelations, +1-650-888-0902, sannes@dynavax.com
Web site: http://www.dynavax.com/
